Hypertension Management Guidelines

Initial Therapy and Treatment Strategies

The International Society of Hypertension recommends a step-wise approach to hypertension treatment, starting with either an ACE inhibitor or ARB, but not both, particularly in patients with albuminuria 1
The Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines state that the use of a combination of ACE-Is and ARBs as a dual blockade of the RAS cannot be recommended due to increased adverse events, particularly impaired kidney function and hyperkalemia 2
The International Society of Hypertension guidelines suggest adding a dihydropyridine calcium channel blocker (CCB) or thiazide/thiazide-like diuretic if blood pressure targets are not achieved with initial therapy 1
For patients who require further blood pressure lowering, the International Society of Hypertension guidelines recommend adding a third agent from the above classes (ACE inhibitor/ARB + CCB + thiazide/thiazide-like diuretic) 1

The American Diabetes Association recommends that patients with diabetes and chronic kidney disease (CKD) be treated with ACE inhibitors or ARBs as preferred first-line agents for blood pressure treatment, especially with albuminuria ≥300 mg/g Cr 3
The International Society of Hypertension guidelines suggest considering a low-dose ARB + dihydropyridine CCB or a dihydropyridine CCB + thiazide-like diuretic as initial therapy for black patients 1

The Kidney International guidelines recommend monitoring serum creatinine and potassium within 2-4 weeks after starting or changing dose, and continuing therapy unless serum creatinine rises by more than 30% within 4 weeks 4
The Kidney International guidelines also recommend managing hyperkalemia when possible rather than immediately stopping the medication 4
The American College of Cardiology and American Heart Association recommend against the routine combined use of an ACE inhibitor and ARB due to increased risks of adverse effects without significant clinical benefit, with a Class III: Harm recommendation 5, 6, 7, 8

Beta-blockers, specifically bisoprolol, carvedilol, or sustained-release metoprolol succinate, are recommended with a Class I recommendation to reduce mortality, regardless of presence of CAD, diabetes, gender, or race 5, 6
Mineralocorticoid Receptor Antagonists (MRAs), such as spironolactone or eplerenone, are recommended for patients with NYHA class II-IV heart failure, LVEF ≤35%, or prior cardiovascular hospitalization, with careful monitoring for hyperkalemia 6
Diuretics, including loop diuretics or thiazides, are useful for managing fluid overload and congestion, and can act synergistically with existing medications 9
Calcium Channel Blockers (CCBs), specifically dihydropyridine CCBs like amlodine or felodipine, are preferred, while non-dihydropyridine CCBs like verapamil or diltiazem should be avoided due to negative inotropic effects 9, 10
The combination of hydralazine and isosorbide dinitrate is particularly beneficial for African American patients with NYHA class III-IV heart failure 6
ACE inhibitors remain first-line therapy for inhibition of the renin-angiotensin system in heart failure, according to the American College of Cardiology/American Heart Association guidelines 7, 8
ARBs should be used as alternatives when patients cannot tolerate ACE inhibitors, typically due to cough or angioedema, as recommended by the American College of Cardiology/American Heart Association guidelines 7, 11

Assess clinical status and add MRA if renal function permits for patients with heart failure and LVEF ≤35% 6
Consider comorbidities, such as fluid overload, coronary artery disease, or proteinuria/CKD, when selecting medications 5, 9
Monitor blood pressure, renal function, and potassium levels within 1-2 weeks of medication initiation and after dose changes, with particular caution when using MRAs with dual RAS blockade 5, 7, 12
High-risk patients, including those with systolic BP <80 mmHg, low serum sodium, diabetes mellitus, or impaired renal function, require closer monitoring 5, 7, 12
Routine combined use of ACE inhibitor, ARB, and aldosterone antagonist is potentially harmful, according to the European Society of Cardiology guidelines 9, 7, 8
If maintaining dual RAS blockade, use lower doses of each agent and monitor very closely 5, 7
Consider discontinuing one of the RAS blockers and optimizing the remaining one before adding new agents 5, 7
The European Society of Cardiology recommends specific target doses for ARBs in heart failure management, including:
ARB Target Dose
Candesartan 32 mg once daily
Valsartan 160 mg twice daily
Losartan 50-100 mg once daily
11, 12